

ARIA CLASSIFICATION GUIDE FOR ADULT REGIMENS

The diagnosis entered by the clinician using the ICD-10 code directs the prescriber to the appropriate disease folder in the prescribing window when starting treatment. Therefore the following disease sites should be assigned when building and validating regimens, only those listed below should be used as these have been tested and it is recognised that some disease sites do not function as expected. In some circumstances it may be necessary to assign a Cancer Category when a disease site is broken down by cell type e.g. leukaemia. Due to the large number of anatomical sites for Upper GI tumours, it has been agreed that all protocols pre-fixed UGI should be assigned to the disease site Digestive (Misc.), however the clinician will not automatically be directed to this folder after entering the diagnosis. In some circumstances it may be necessary to assign more than one disease site e.g. Colon and Rectum for a regimen used in both of these disease sites.

| DISEASE SITE | NON-TRIALS CANCER CATEGORY | CLINICAL TRIALS CANCER CATEGORY | NOTES |
|------------------------|------------------------------|--|----------------------------|
| Anal Canal | | Clinical Trials – Anal Cancer | |
| Bladder | | Clinical Trials – Bladder | |
| Brain | | Clinical Trials – Brain | |
| Breast | Early breast cancer | Clinical Trials – Breast | |
| | Metastatic breast cancer | | |
| Cervical | | Clinical Trials - Cervical | |
| Colon | | Clinical Trials – Colon | |
| Digestive (Misc.) | | Clinical Trials – Digestive | Use for all UGI regimens |
| Haematology | Myelodysplasia | Clinical Trials – Myelodysplasia | |
| | Myeloproliferative Disorders | Clinical Trials – Myeloproliferative | |
| Head & Neck | | Clinical Trials – Head & Neck | |
| Heart | Malignant Thymoma | Clinical Trials – Malignant Thymoma | |
| Hodgkin’s Disease | | Clinical Trials – Hodgkin’s Disease | Use for Hodgkin’s Lymphoma |
| Kidney | | Clinical Trials – Kidney | Use for Renal Cell |
| Leukaemia | ALL | Clinical Trials – ALL | |
| | AML | Clinical Trials – AML | |
| | Hairy Cell | Clinical Trials – Hairy Cell | |
| | CLL | Clinical Trials – CLL | |
| | CML | Clinical Trials – CML | |
| Lung | NSCLC | Clinical Trials – NSCLC | |
| | SCLC | Clinical Trials – SCLC | |
| Melanoma | | Clinical Trials – Melanoma | |
| Myeloma | | Clinical Trials – Myeloma | |
| Non-Hodgkin’s Lymphoma | | Clinical Trials – Non-Hodgkin’s Lymphoma | |
| Ovarian | | Clinical Trials – Ovarian | |
| Penis | | Clinical Trials – Penis | |

| | | | | | | |
|---|-----------|----------------------|-----------------------|---------------------------|--------------|--------------------|
| SOP No | KMCCEP006 | Version | 6 | Supersedes version | 5 | Page 1 of 2 |
| Written By | H Downs | Authorised by | SACT Governance Group | Date | January 2025 | |
| KMCC document: No responsibility will be accepted for the accuracy of this information when used elsewhere. | | | | | | |

ARIA CLASSIFICATION GUIDE FOR ADULT REGIMENS

| | | | |
|----------------------|------------------------------|---|--|
| Pleural Mesothelioma | | Clinical Trials – Pleural Mesothelioma | |
| Prostate | | Clinical Trials – Prostate | |
| Rectal | | Clinical Trials – Rectal | |
| Skin | | Clinical Trials – Basal Cell | |
| | Cutaneous Squamous Carcinoma | Clinical Trials – Cutaneous Squamous | |
| | Merkel Cell Carcinoma | Clinical Trials – Merkel Cell Carcinoma | |
| Testicular | | Clinical Trials - Testicular | |
| Thyroid | | Clinical Trials – Thyroid | |
| Uterine | | Clinical Trials - Uterine | |